eTheRNA has entered a new phase in its young but promising history. The company is well positioned and adequately financed to complete phase I and II clinical studies with its mRNA-based TriMix platform for the treatment of advanced melanoma and breast cancer. eTheRNA plays a pioneering role in the development of in vivo mRNA-therapies that deliver tumor antigens to dendritic cells.
eTheRNA groups team members who are all passionate about mRNA technology and who wish to contribute to the development of truly innovative immunotherapies that can help millions of patients by combatting their disease.
Do you share our passion and are you the best in your area? Send us your spontaneous application.
There are currently no vacancies available. Please revisit this web page in the near future.